ArticleNature biotechnology2026
High-fidelity fast fluorescence lifetime imaging by event-based denoising.
Article in Nature biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Fluorescence lifetime imaging microscopy (FLIM) enables quantitative measurement of molecular environments, interactions and protein conformations. However, a large number of photons are required for accurate lifetime determination, restricting its practical applications in fast deep-tissue imaging. Here, we present event-based first-photon FLIM (EFLIM), a self-supervised denoising method that infers fluorescence lifetime at extremely low light. By representing each excitation event as a binary process instead of histogram accumulation, EFLIM reduces photon requirement by over two orders of magnitude compared to state-of-the-art algorithms, leading to an apparent mean lifetime measurement below one photon per pixel with strong robustness to intensity artifacts. To demonstrate EFLIM's applicability, we observed transient intracellular dynamics of ligand-dependent molecular states, captured putative vesicle-mediated contacts between different lymphocytes through multiplexed imaging in a single spectral channel and achieved rapid label-free visualization of tumor heterogeneity in human glioma tissue. These results illustrate EFLIM's strong potential in neuroscience, cell biology, immunology and pathology by probing dynamic molecular processes in vivo.
Identifiers
42458053What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.